A systematic review and meta-analysis of remdesivir for the treatment of COVID-19 showed that data from randomized controlled trials (n=5 trials) indicated significant improvement in the 28-day recovery rate, need for low flow oxygen support through day 14, and mechanical ventilation or extracorporeal membrane oxygenation requirement through days 14 to 28 of follow-up in the remdesivir group. Data from non-randomized intervention studies (n=5 studies) showed significantly lower need for low flow oxygen support through days 14 to 28 in the remdesivir group, and lower risk of 28-day mortality. There were no significant differences between the 5- and 10-day remdesivir courses, and the authors suggest that the 5-day regimen may provide similar benefits while causing fewer adverse reactions.<\/p>\n
Rezagholizadeh et al. (Feb 2021). Remdesivir for Treatment of COVID-19; an Updated Systematic Review and Meta-Analysis. European Journal of Pharmacology. <\/i>https:\/\/doi.org\/10.1016\/j.ejphar.2021.173926<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" A systematic review and meta-analysis of remdesivir for the treatment of COVID-19 showed that data from randomized controlled trials (n=5 trials) indicated significant improvement in the 28-day recovery rate, need for low flow oxygen support through day 14, and mechanical ventilation or extracorporeal membrane oxygenation requirement through days 14 to 28 of follow-up in the…<\/p>\n